AbbVie vs Moderna
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put AbbVie and Moderna side by side, using each one’s latest annual report. Here is what stands out:
- AbbVie is the larger business, with $61.2B of revenue in fiscal 2025 against $1.9B for Moderna, about 31 times as much.
- AbbVie grew revenue faster (8.6%, against −39.9%).
- AbbVie kept more of each dollar of sales as operating profit (24.7% operating margin, against −158.1%).
- AbbVie turned more of its sales into free cash flow (29.1% FCF margin, against −106.2%).
- AbbVie earned a higher return on the capital invested in it (15.7%, against −65.4%).
Who comes out ahead
Of the 9 measures where higher (or lower) is clearly better, how many each company leads.
AbbVie
ABBV
8/9
Revenue growthGross marginOperating marginNet marginFCF marginReturn on capitalPiotroski F-scoreShare count change
Moderna
MRNA
1/9
5-year growth
Side by side
Best in the row
| Latest fiscal year | ABBV FY25 | MRNA FY25 |
|---|---|---|
| Size | ||
| Market cap | $507.8B | $79.1B |
| Revenue | $61.2B | $1.9B |
| Free cash flow | $17.8B | −$2.1B |
| Net income | $4.2B | −$2.8B |
| Growth | ||
| Revenue growth | 8.6% | −39.9% |
| 5-year growth | 6.0% | 19.3% |
| Share count change | 0.0% | 1.3% |
| Profitability | ||
| Gross margin | 70.2% | 55.4% |
| Operating margin | 24.7% | −158.1% |
| Net margin | 6.9% | −145.2% |
| FCF margin | 29.1% | −106.2% |
| Return on capital | 15.7% | −65.4% |
| Return on equity | — | −28.9% |
| Balance sheet | ||
| Net debt | $61.8B | −$5.2B |
| Net debt / EBITDA | 2.7x | — |
| Dividends and buybacks | $12.6B | $2.0M |
| Valuation & quality | ||
| P/E | 81.0x | — |
| Piotroski F-score | 7 | 2 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.